Spyre Therapeutics
SYRE
50 hedge funds and large institutions have $19.2M invested in Spyre Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 13 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.15% less ownership
Funds ownership: 2.92% → 2.77% (-0.15%)
9% less funds holding
Funds holding: 55 → 50 (-5)
18% less capital invested
Capital invested by funds: $23.5M → $19.2M (-$4.32M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.67M |
| 2 |
PVI
Pura Vida Investments
New York
|
+$754K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$663K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$647K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$317K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$1.34M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.31M |
| 3 |
SCM
Sio Capital Management
New York
|
-$1.2M |
| 4 |
Goldman Sachs
New York
|
-$482K |
| 5 |
BlackRock
New York
|
-$278K |
SYRE Hedge Fund Activity: Q4 2022 in Review
50 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2022, worth a combined $19.2M — down 18% from $23.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of SYRE and 8 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, adding an estimated $1.67M. The largest seller was Pictet Asset Management (Switzerland), exiting entirely with an estimated $1.34M sold.
- 50 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2022, down from 55 in Q3 2022.
- Funds reported $19.2M of Spyre Therapeutics stock for Q4 2022, down 18% quarter-over-quarter.
- 8 funds opened new Spyre Therapeutics positions in Q4 2022 and 13 closed out, a net change of -5 holders.
- The largest Spyre Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $1.67M added.
- The largest Spyre Therapeutics seller in Q4 2022 was Pictet Asset Management (Switzerland), an estimated $1.34M sold.
Based on aggregated 13F filings for Q4 2022.